A Randomized, 6-period, 6-treatment, Single-dose, Open-label, Single-center, Crossover Study to Assess the Relative Bioavailability of Different Formulations of AZD5718 and the Food Effect on the Selected Formulation of AZD5718 in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 26 Apr 2018
At a glance
- Drugs AZD 5718 (Primary)
- Indications Coronary artery disease
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 31 Aug 2018 Biomarkers information updated
- 20 Apr 2018 Status changed from recruiting to completed.
- 13 Apr 2018 Planned End Date changed from 30 Apr 2018 to 18 Apr 2018.